Trial reportInternational journal for parasitology. Drugs and drug resistance2025
Evaluating the efficacy of different praziquantel treatment regimens using egg and circulating anodic antigen (CAA) detection methods in a Schistosoma mansoni endemic area in northeastern Brazil.
Trial report in International journal for parasitology. Drugs and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Schistosomiasis in Yemen: Focal Persistence, Possible Resurgence, and Challenges to Elimination.Research and reports in tropical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluated the efficacy of different treatment regimens with PZQ against Schistosoma mansoni infection. Residents of the Patioba and Colônia Miranda villages (Sergipe, Brazil) with a confirmed diagnosis of S. mansoni infection were randomized into one of the study groups and treated with a standard dose of PZQ (Group 1); with two doses spaced 24 hours apart (Group 2); or with two doses spaced 30 days apart (Group 3). Efficacy was assessed 30 days after the final treatment, based on the detection of eggs in feces using the Kato-Katz (KK) method and on the detection of CAA in urine using the Up-Converting Particle Lateral Flow (UCP-LF) assay. A total of 88 participants, who tested positive for infection by KK and UCP-LF CAA at baseline, were included in the statistical analysis. Cure rates (CRs) reached 100 % in all three study groups, according to KK. The UCP-LF CAA revealed that not all participants were cured, with the highest cure rate observed in Group 2 (69.6 %%), followed by Group 3 (57.7 %) and Group 1 (43.8 %). An Intensity Reduction Rate (IRR) of 100 % and >97 % was observed in all groups, based on KK and UCP-LF CAA, respectively. Reduction in S. mansoni burden was observed over time, with the IRR in all groups exceeding the efficacy threshold established by the WHO (>90 %). Cure rates varied according to the diagnostic method used, being overestimated when based on egg quantification, highlighting the importance of using more sensitive tools for the detection of active infections and monitoring the efficacy of PZQ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.